Will Achillion Pharmaceuticals, Inc. (ACHN) Go Down Anytime Soon?

September 17, 2017 - By Nellie Frank

Investors sentiment decreased to 1.09 in Q4 2016. Its down 0.43, from 1.52 in 2016Q3. It worsened, as 32 investors sold Achillion Pharmaceuticals, Inc. shares while 33 reduced holdings. 22 funds opened positions while 49 raised stakes. 97.41 million shares or 7.54% less from 105.36 million shares in 2016Q3 were reported.
Doheny Asset Ca stated it has 0.08% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Integral Derivatives Ltd Co holds 13,754 shares or 0% of its portfolio. Orbimed Ltd Liability Company accumulated 13.11 million shares. Emory University owns 454,102 shares or 1.85% of their US portfolio. Bancorp Of America De holds 536,923 shares. Da Davidson has invested 0.01% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). 978,600 are owned by Spark Invest Mngmt Lc. State Street Corporation reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Raymond James Assoc reported 0% stake. Vanguard Grp owns 8.94 million shares. Globeflex Capital Ltd Partnership holds 0.09% or 87,000 shares in its portfolio. Blackrock Institutional Trust Co Na has 3.87M shares. Centers Of America Inc, North Dakota-based fund reported 13,733 shares. Blackrock Investment Management Limited Liability owns 435,720 shares or 0% of their US portfolio.

The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a huge mover today! The stock increased 3.64% or $0.13 on September 15, reaching $3.7. About 2.39M shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 47.61% since September 17, 2016 and is downtrending. It has underperformed by 64.31% the S&P500.
The move comes after 7 months positive chart setup for the $506.02 million company. It was reported on Sep, 17 by Barchart.com. We have $3.85 PT which if reached, will make NASDAQ:ACHN worth $20.24M more.

Analysts await Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report earnings on November, 2. They expect $-0.18 EPS, down 20.00 % or $0.03 from last year’s $-0.15 per share. After $-0.16 actual EPS reported by Achillion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 12.50 % negative EPS growth.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Coverage

Among 10 analysts covering Achillion Pharma (NASDAQ:ACHN), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Achillion Pharma had 22 analyst reports since August 13, 2015 according to SRatingsIntel. The stock has “Hold” rating by Robert W. Baird on Monday, September 11. Chardan Capital Markets initiated it with “Sell” rating and $4 target in Thursday, July 14 report. The rating was maintained by Leerink Swann with “Buy” on Friday, August 11. The stock has “Hold” rating by Jefferies on Wednesday, September 9. The stock has “Buy” rating by UBS on Tuesday, September 8. The company was upgraded on Thursday, July 7 by JMP Securities. As per Thursday, February 2, the company rating was initiated by Ladenburg Thalmann. The stock has “Market Perform” rating by Leerink Swann on Wednesday, May 4. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Outperform” rating by Wedbush on Friday, September 23. Robert W. Baird downgraded the shares of ACHN in report on Thursday, August 10 to “Neutral” rating.

More recent Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) news were published by: Seekingalpha.com which released: “Achillion Is Crushed As Johnson & Johnson Heads For The Exit” on September 14, 2017. Also 247Wallst.com published the news titled: “Achillion Pharma Slides After Hep C Deal Is Terminated” on September 11, 2017. Nasdaq.com‘s news article titled: “Mid-Day Market Update: Dow Up 1%; Achillion Pharmaceuticals Shares Plunge” with publication date: September 11, 2017 was also an interesting one.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $506.02 million. The Firm is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. It currently has negative earnings. The Firm is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.